
Haemonetics (HAE) Stock Forecast & Price Target
Haemonetics (HAE) Analyst Ratings
Bulls say
Haemonetics Corp is poised for significant growth driven by a robust emphasis on its plasma and hospital segments, which have demonstrated strong sales trajectories, including a notable 23.2% growth in plasma (excluding CSL) and 13.0% in Blood Management Technologies. The company is expected to sustain mid-single-digit growth rates, bolstered by accelerating revenue from non-CSL Plasma and double-digit growth from its hospital product offerings, promising improved operating margins and earnings. In addition, Haemonetics’s strategic focus on high-growth MedTech products and potential accretive acquisitions indicates a solid pathway for maintaining a favorable financial outlook amid evolving market dynamics.
Bears say
Haemonetics Corp's outlook has turned negative due to anticipated declines in its Interventional Technologies segment, which is expected to negatively impact overall gross margins given its historically high profit levels. Revenue growth projections have shifted to the low-single digits, with challenges in both the plasma and hospital segments contributing to lower-than-expected operating margins and earnings per share. Additionally, increased competition in the vascular closure device market raises concerns regarding the sustainability of Haemonetics's growth trajectory, further raising the risk of multiple compression for its shares.
This aggregate rating is based on analysts' research of Haemonetics and is not a guaranteed prediction by Public.com or investment advice.
Haemonetics (HAE) Analyst Forecast & Price Prediction
Start investing in Haemonetics (HAE)
Order type
Buy in
Order amount
Est. shares
0 shares